stockrow
Friday 6 November 2026
Export BCRX’s income statement to Excel — free account
BioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
7.44
0.19
−2.49%
Follow BCRX
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 4 | 7 |
+8 more TTM periods Free account |
| 91.60% | 87.84% | 91.07% | (88.68%) | ||
| (69.33%) | (75.79%) | (96.92%) | 52.53% | ||
ROIC |
0.00% | (610.55%) | (356.26%) | 245.61% | |
Return on Tangible Assets |
(106.73%) | (135.02%) | (244.12%) | 121.56% | |
Average Days of Receivables |
46.23 | 42.98 | 45.03 | 44.57 | |
Free Cash Flow per Share |
1.43 | 1.47 | 1.28 | 1.65 | |
Free Cash Flow |
366.40 | 373.93 | 310.92 | 345.45 | |
Capital Expenditures |
(1.10) | (2.21) | (2.18) | (1.92) | |
| Other line items | |||||
Cash ROIC |
(92.20%) | 50.66% | 57.00% | 54.26% | |
Accounts Receivable Turnover |
9.02 | 9.32 | 8.74 | 9.41 | |
Accounts Payable Turnover |
2.02 | 2.09 | 1.89 | 1.39 | |
Inventory Turnover |
2.14 | 3.77 | 3.09 | 2.83 | |
Average Days of Payables |
261.97 | 199.87 | 201.15 | 302.83 | |
Days of Inventory on Hand |
246.89 | 105.63 | 109.86 | 103.29 | |
Tax Rate |
0.01 | 0.01 | 0.01 | (0.01) | |
Research and Development Expense of Revenue |
21.98% | 21.02% | 21.36% | 18.99% | |
Selling, General and Administrative Expense of Revenue |
33.44% | 35.86% | 40.73% | 39.85% | |
Share Based Compensation of Revenue |
7.15% | 7.77% | 9.00% | 9.72% | |
Interest Coverage |
(3.77) | (4.16) | (5.08) | 4.32 | |
Operating CF/Net income |
(1.02) | (0.98) | (0.68) | 1.32 | |
Depreciation/Fixed assets |
0.00 | (0.03) | (0.10) | (0.33) | |
Capex/Depreciation |
0.00 | 7.08 | 2.24 | 0.65 | |
Revenue per Share |
3.76 | 3.70 | 3.66 | 4.17 | |
Operating CF per Share |
1.44 | 1.48 | 1.29 | 1.66 | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 4 Nov 2026